Advancis Pharmaceutical to Announce First Quarter 2007 Financial Results on May 8, 2007
03 Mayo 2007 - 8:00AM
PR Newswire (US)
Conference Call and Webcast to Follow GERMANTOWN, Md., May 3
/PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation
(NASDAQ:AVNC), a pharmaceutical company focused on developing and
commercializing novel anti-infective products, today announced it
will release results for the quarter ended March 31, 2007, on
Tuesday, May 8, 2007, before the market opens. A full text copy of
the release will be disseminated at that time. Edward M. Rudnic,
Ph.D., president and chief executive officer, will host a
conference call to discuss the results and other corporate
developments at 10:30 AM ET on Tuesday, May 8, 2007. Also
participating on the call will be Robert C. Low, vice president,
finance and CFO. To participate in the conference call, dial the
appropriate number below shortly before the 10:30 AM start time and
ask for the Advancis Pharmaceutical conference call hosted by Dr.
Rudnic. The teleconference dial-in numbers are as follows: Domestic
callers 1-800-813-8504 International callers 1-706-643-7752 The
conference call will be broadcast simultaneously and archived on
the Company's web site, http://www.advancispharm.com/. Investors
should go to the web site at least 15 minutes early to register,
download, and install any necessary audio software. A replay of the
call will be available on Tuesday, May 8, 2007, beginning at 12:30
PM ET and will be accessible until Tuesday, May 15, 2007, at 5:00
PM ET. The replay call-in number is 1-800-642-1687 for domestic
callers and 1- 706-645-9291 for international callers. The access
number is 8091179. About Advancis Pharmaceutical: Advancis
Pharmaceutical Corporation (NASDAQ:AVNC) is a pharmaceutical
company focused on the development and commercialization of
anti-infective drug products that fulfill substantial unmet medical
needs in the treatment of infectious disease. The Company is
developing anti-infective drugs based on its novel biological
finding that bacteria exposed to antibiotics in front- loaded
staccato bursts, or "pulses," are killed more efficiently than
those under standard treatment regimens. Based on this finding,
Advancis has developed a proprietary, once-a-day pulsatile delivery
technology called PULSYSTM. By examining the resistance patterns of
bacteria and applying its delivery technologies, Advancis has the
potential to redefine infectious disease therapy and significantly
improve drug efficacy, shorten length of therapy, and reduce drug
resistance versus currently available antibacterial products. For
more on Advancis, please visit http://www.advancispharm.com/.
DATASOURCE: Advancis Pharmaceutical Corporation CONTACT: Bob
Bannon, Vice President, Investor Relations & Corporate
Communications, of Advancis Pharmaceutical Corp., +1-301-944-6710,
Web site: http://www.advancispharm.com/
Copyright
Advancis (NASDAQ:AVNC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Advancis (NASDAQ:AVNC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Advancis Pharmaceutical (MM) (NASDAQ): 0 recent articles
Más de Advancis Pharmaceutical (MM) Artículos de Noticias